몰타 - 영어 - Medicines Authority

hetero europe s.l. viladecans business park - edificio brasil catalunya 83-85 08840 viladecans, spain - temozolomide - hard capsule - temozolomide 140 mg - antineoplastic agents

몰타 - 영어 - Medicines Authority

hetero europe s.l. viladecans business park - edificio brasil catalunya 83-85 08840 viladecans, spain - temozolomide - hard capsule - temozolomide 180 mg - antineoplastic agents

몰타 - 영어 - Medicines Authority

hetero europe s.l. viladecans business park - edificio brasil catalunya 83-85 08840 viladecans, spain - temozolomide - hard capsule - temozolomide 250 mg - antineoplastic agents

몰타 - 영어 - Medicines Authority

hetero europe s.l. viladecans business park - edificio brasil catalunya 83-85 08840 viladecans, spain - temozolomide - hard capsule - temozolomide 5 mg - antineoplastic agents

몰타 - 영어 - Medicines Authority

hetero europe s.l. viladecans business park - edificio brasil catalunya 83-85 08840 viladecans, spain - temozolomide - hard capsule - temozolomide 20 mg - antineoplastic agents

유럽 연합 - 영어 - EMA (European Medicines Agency)

hexal ag - temozolomide - glioma; glioblastoma - antineoplastic agents - for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (rt) and subsequently as monotherapy treatment.for the treatment of children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.

유럽 연합 - 영어 - EMA (European Medicines Agency)

sandoz gmbh - temozolomide - glioma; glioblastoma - antineoplastic agents - for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (rt) and subsequently as monotherapy treatment.for the treatment of children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.

미국 - 영어 - NLM (National Library of Medicine)

physicians total care, inc. - temozolomide (unii: yf1k15m17y) (temozolomide - unii:yf1k15m17y) - temozolomide 5 mg - temodar® (temozolomide) is indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment. temodar is indicated for the treatment of adult patients with refractory anaplastic astrocytoma, i.e., patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine. temodar (temozolomide) is contraindicated in patients who have a history of hypersensitivity reaction (such as urticaria, allergic reaction including anaphylaxis, toxic epidermal necrolysis, and stevens-johnson syndrome) to any of its components. temodar is also contraindicated in patients who have a history of hypersensitivity to dtic, since both drugs are metabolized to 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide (mtic). pregnancy category d. see warnings and precautions section. temodar can cause fetal harm when administered to a pregnant woman. five consecutive days of oral temozolomide administration of 0.38

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - temozolomide, quantity: 180 mg - capsule - excipient ingredients: purified water; purified talc; gelatin; silicon dioxide; lactose; sodium starch glycollate; titanium dioxide; iron oxide red; tartaric acid; stearic acid; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - temozolomide is indicated for the treatment of:,? patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,? recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as first line treatment for patients with advanced metastatic malignant melanoma.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - temozolomide, quantity: 5 mg - capsule - excipient ingredients: purified water; purified talc; sodium starch glycollate; titanium dioxide; gelatin; iron oxide yellow; stearic acid; indigo carmine; lactose; silicon dioxide; tartaric acid; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - temozolomide is indicated for the treatment of:,? patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,? recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as first line treatment for patients with advanced metastatic malignant melanoma.